Status:
COMPLETED
Identifying the Optimal Neural Target for Misophonia Interventions
Lead Sponsor:
Duke University
Collaborating Sponsors:
Misophonia Research Fund
Conditions:
Misophonia
Emotion Dysregulation
Eligibility:
All Genders
18-55 years
Phase:
NA
Brief Summary
Misophonia, the inability to tolerate certain repetitive aversive sounds that are common, is gaining recognition as a debilitating condition. It is not a well-understood condition and there are no kno...
Detailed Description
Consistent with NIMH strategic priorities, neural targets that account for individual differences are needed for the next generation of mental health interventions. Misophonia, the inability to tolera...
Eligibility Criteria
Inclusion
- Interested participants will be excluded if:
- current or past history of mania or psychosis,
- verbal IQ \< 70,
- not medically cleared for TMS or fMRI (for example taking medications known to reduce the seizure threshold such as Lamictal, Lithium, Clozaril, stimulants including the ADHD medications (e.g. Ritalin, Adderall), Wellbutrin/Buproprion, Provigil (Modafinil), Aminophylline, and Theophylline, implants, TBI, stroke, etc),
- going to jail in the next 2 months,
- pregnant,
- high risk for suicide
- moderate/severe current alcohol or substance dependence,
- cannot come to Duke for the three study visits.
- Inclusion criteria are:
- stable psychotherapy and medication for at least 4 weeks
- self reports high emotional dysregulation OR misophonia
- Participants will be matched on gender and age between the two groups
Exclusion
Key Trial Info
Start Date :
October 28 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 28 2022
Estimated Enrollment :
59 Patients enrolled
Trial Details
Trial ID
NCT04348591
Start Date
October 28 2020
End Date
May 28 2022
Last Update
August 25 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Duke University Medical Center-Civitan Bldg
Durham, North Carolina, United States, 27710